Xencor (XNCR) Competitors $11.00 +0.14 (+1.26%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. SRRK, AKRO, VKTX, XENE, CPRX, MOR, PTGX, HCM, IMVT, and APLSShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Scholar Rock (SRRK), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), Protagonist Therapeutics (PTGX), HUTCHMED (HCM), Immunovant (IMVT), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Scholar Rock Akero Therapeutics Viking Therapeutics Xenon Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics HUTCHMED Immunovant Apellis Pharmaceuticals Scholar Rock (NASDAQ:SRRK) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media favor SRRK or XNCR? In the previous week, Scholar Rock had 14 more articles in the media than Xencor. MarketBeat recorded 21 mentions for Scholar Rock and 7 mentions for Xencor. Scholar Rock's average media sentiment score of 1.18 beat Xencor's score of 1.15 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 15 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, SRRK or XNCR? Xencor has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M93.63-$165.79M-$2.45-13.37Xencor$110.49M6.99-$126.09M-$3.51-3.09 Is SRRK or XNCR more profitable? Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -145.60% -91.83% Xencor -232.77%-30.92%-21.74% Do analysts prefer SRRK or XNCR? Scholar Rock presently has a consensus target price of $42.67, suggesting a potential upside of 30.24%. Xencor has a consensus target price of $32.86, suggesting a potential upside of 202.55%. Given Xencor's stronger consensus rating and higher possible upside, analysts plainly believe Xencor is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Xencor 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more risk and volatility, SRRK or XNCR? Scholar Rock has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Does the MarketBeat Community prefer SRRK or XNCR? Xencor received 340 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 73.24% of users gave Xencor an outperform vote while only 66.27% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16966.27% Underperform Votes8633.73% XencorOutperform Votes50973.24% Underperform Votes18626.76% Do insiders & institutionals have more ownership in SRRK or XNCR? 91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.2% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryXencor beats Scholar Rock on 12 of the 19 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$772.71M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.397.3222.5118.54Price / Sales6.99241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.996.486.734.25Net Income-$126.09M$143.41M$3.22B$248.18M7 Day Performance3.33%2.58%1.38%1.03%1 Month Performance10.59%5.00%2.79%2.70%1 Year Performance-54.04%-3.72%15.41%4.05% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.5155 of 5 stars$11.00+1.3%$32.86+198.8%-54.6%$780.04M$110.49M-3.43280Upcoming EarningsAnalyst ForecastPositive NewsSRRKScholar Rock4.0538 of 5 stars$31.67-3.5%$42.67+34.7%+119.0%$3.00B$33.19M-13.48140Upcoming EarningsInsider TradeNews CoveragePositive NewsAKROAkero Therapeutics3.7931 of 5 stars$42.17+2.9%$76.29+80.9%+125.6%$2.92BN/A-11.2530Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.5162 of 5 stars$25.94+3.8%$87.15+236.0%-62.6%$2.91BN/A-25.9420Analyst UpgradeOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.5671 of 5 stars$37.84+0.6%$56.78+50.0%-10.4%$2.90B$9.43M-13.42210Upcoming EarningsOptions VolumeNews CoveragePositive NewsCPRXCatalyst Pharmaceuticals4.6832 of 5 stars$23.63+0.8%$32.29+36.6%+59.7%$2.88B$491.73M20.0380Upcoming EarningsPositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4712 of 5 stars$44.39-0.2%$65.44+47.4%+76.0%$2.72B$434.43M16.69120Upcoming EarningsNews CoveragePositive NewsHCMHUTCHMED1.247 of 5 stars$15.08+3.2%$19.00+26.0%-21.1%$2.63B$630.20M0.001,760Upcoming EarningsShort Interest ↑IMVTImmunovant2.2341 of 5 stars$15.42+4.8%$38.33+148.6%-44.2%$2.62BN/A-5.89120APLSApellis Pharmaceuticals4.1347 of 5 stars$17.96+2.7%$45.35+152.5%-56.4%$2.51B$781.37M-8.85770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Scholar Rock Alternatives Akero Therapeutics Alternatives Viking Therapeutics Alternatives Xenon Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives MorphoSys Alternatives Protagonist Therapeutics Alternatives HUTCHMED Alternatives Immunovant Alternatives Apellis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.